ID   SPTN1_RAT               Reviewed;        2472 AA.
AC   P16086; O88663; P70477;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   16-NOV-2001, sequence version 2.
DT   24-JUL-2024, entry version 211.
DE   RecName: Full=Spectrin alpha chain, non-erythrocytic 1;
DE   AltName: Full=Alpha-II spectrin;
DE   AltName: Full=Fodrin alpha chain;
GN   Name=Sptan1; Synonyms=Spna2, Spta2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Wistar; TISSUE=Liver;
RA   Kalamaraki P., Gazzotti P.;
RT   "Structural and functional characterization of the calmodulin and calpain
RT   binding domains of rat liver alphaII spectrin.";
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RA   Zhou D., Ursitti J.A., Porter N.C., Randall W.R., Bloch R.J.;
RT   "Expressional cloning of alpha-fodrin from rat skeletal muscle.";
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1292-2472.
RC   TISSUE=Kidney;
RX   PubMed=2753883; DOI=10.1016/s0021-9258(18)51550-7;
RA   Hong W., Doyle D.;
RT   "Cloning and analysis of cDNA clones for rat kidney alpha-spectrin.";
RL   J. Biol. Chem. 264:12758-12764(1989).
RN   [4]
RP   PROTEIN SEQUENCE OF 286-295; 1226-1237; 1335-1343; 1370-1380; 1592-1605;
RP   1620-1630; 1689-1698; 1795-1803; 1985-1995; 2316-2326; 2405-2414 AND
RP   2427-2435, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain, and Spinal cord;
RA   Lubec G., Afjehi-Sadat L., Kang S.U.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [5]
RP   PHOSPHORYLATION AT TYR-1176, MUTAGENESIS OF GLU-985; LYS-1002; PRO-1017 AND
RP   TYR-1176, AND INTERACTION WITH ACP1.
RX   PubMed=11971983; DOI=10.1128/mcb.22.10.3527-3536.2002;
RA   Nicolas G., Fournier C.M., Galand C., Malbert-Colas L., Bournier O.,
RA   Kroviarski Y., Bourgeois M., Camonis J.H., Dhermy D., Grandchamp B.,
RA   Lecomte M.-C.;
RT   "Tyrosine phosphorylation regulates alpha II spectrin cleavage by
RT   calpain.";
RL   Mol. Cell. Biol. 22:3527-3536(2002).
RN   [6]
RP   IDENTIFICATION IN A COMPLEX WITH ACTN4; CASK; IQGAP1; MAGI2; NPHS1 AND
RP   SPTBN1, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND DEVELOPMENTAL STAGE.
RC   STRAIN=Sprague-Dawley; TISSUE=Renal glomerulus;
RX   PubMed=15994232; DOI=10.1073/pnas.0504166102;
RA   Lehtonen S., Ryan J.J., Kudlicka K., Iino N., Zhou H., Farquhar M.G.;
RT   "Cell junction-associated proteins IQGAP1, MAGI-2, CASK, spectrins, and
RT   alpha-actinin are components of the nephrin multiprotein complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:9814-9819(2005).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1217, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16641100; DOI=10.1073/pnas.0600895103;
RA   Hoffert J.D., Pisitkun T., Wang G., Shen R.-F., Knepper M.A.;
RT   "Quantitative phosphoproteomics of vasopressin-sensitive renal cells:
RT   regulation of aquaporin-2 phosphorylation at two sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7159-7164(2006).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-924; SER-1031; SER-1217 AND
RP   SER-1306, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [9]
RP   INTERACTION WITH SHANK3.
RX   PubMed=23897824; DOI=10.1074/jbc.m112.424747;
RA   Mameza M.G., Dvoretskova E., Bamann M., Hoenck H.H., Gueler T.,
RA   Boeckers T.M., Schoen M., Verpelli C., Sala C., Barsukov I., Dityatev A.,
RA   Kreienkamp H.J.;
RT   "SHANK3 gene mutations associated with autism facilitate ligand binding to
RT   the Shank3 ankyrin repeat region.";
RL   J. Biol. Chem. 288:26697-26708(2013).
CC   -!- FUNCTION: Fodrin, which seems to be involved in secretion, interacts
CC       with calmodulin in a calcium-dependent manner and is thus candidate for
CC       the calcium-dependent movement of the cytoskeleton at the membrane.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Like erythrocyte spectrin, the spectrin-like proteins are
CC       capable of forming dimers which can further associate to tetramers.
CC       Interacts (via C-terminal spectrin repeats) with TRPC4. Interacts with
CC       CALM and EMD. Interacts with isoform 1 of ACP1. Identified in a complex
CC       with ACTN4, CASK, IQGAP1, MAGI2, NPHS1 and SPTBN1. Interacts with
CC       SHANK3 (via ANK repeats). Interacts with CLN3; this interaction
CC       regulates the fodrin localization at the plasma membrane (By
CC       similarity). {ECO:0000250|UniProtKB:Q13813,
CC       ECO:0000269|PubMed:11971983, ECO:0000269|PubMed:15994232,
CC       ECO:0000269|PubMed:23897824}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton {ECO:0000250}. Cytoplasm,
CC       cell cortex {ECO:0000269|PubMed:15994232}. Note=Expressed along the
CC       cell membrane in podocytes and presumptive tubule cells during
CC       glomerulogenesis and is expressed along lateral cell margins in tubule
CC       cells.
CC   -!- TISSUE SPECIFICITY: Expressed in the foot process layer of podocytes in
CC       the kidney glomerulus and in tubules (at protein level).
CC       {ECO:0000269|PubMed:15994232}.
CC   -!- DEVELOPMENTAL STAGE: Expressed throughout glomerulogenesis.
CC       {ECO:0000269|PubMed:15994232}.
CC   -!- PTM: Phosphorylation of Tyr-1176 decreases sensitivity to cleavage by
CC       calpain in vitro. {ECO:0000269|PubMed:11971983}.
CC   -!- SIMILARITY: Belongs to the spectrin family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA40770.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X90845; CAA62350.1; -; mRNA.
DR   EMBL; AF084186; AAC33127.1; -; mRNA.
DR   EMBL; J04828; AAA40770.1; ALT_FRAME; mRNA.
DR   PIR; A32612; A32612.
DR   PIR; S61217; S61217.
DR   RefSeq; NP_741984.2; NM_171983.2.
DR   PDB; 3THK; X-ray; 1.70 A; A/B=967-1035.
DR   PDBsum; 3THK; -.
DR   AlphaFoldDB; P16086; -.
DR   BMRB; P16086; -.
DR   SMR; P16086; -.
DR   BioGRID; 248986; 21.
DR   CORUM; P16086; -.
DR   IntAct; P16086; 5.
DR   MINT; P16086; -.
DR   STRING; 10116.ENSRNOP00000072038; -.
DR   CarbonylDB; P16086; -.
DR   GlyGen; P16086; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P16086; -.
DR   PhosphoSitePlus; P16086; -.
DR   SwissPalm; P16086; -.
DR   jPOST; P16086; -.
DR   PaxDb; 10116-ENSRNOP00000042382; -.
DR   GeneID; 64159; -.
DR   KEGG; rno:64159; -.
DR   UCSC; RGD:621714; rat.
DR   AGR; RGD:621714; -.
DR   CTD; 6709; -.
DR   RGD; 621714; Sptan1.
DR   VEuPathDB; HostDB:ENSRNOG00000015396; -.
DR   eggNOG; KOG0040; Eukaryota.
DR   InParanoid; P16086; -.
DR   OrthoDB; 2872403at2759; -.
DR   PhylomeDB; P16086; -.
DR   Reactome; R-RNO-264870; Caspase-mediated cleavage of cytoskeletal proteins.
DR   Reactome; R-RNO-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-RNO-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-RNO-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   Reactome; R-RNO-6807878; COPI-mediated anterograde transport.
DR   Reactome; R-RNO-9013420; RHOU GTPase cycle.
DR   Reactome; R-RNO-9013424; RHOV GTPase cycle.
DR   EvolutionaryTrace; P16086; -.
DR   PRO; PR:P16086; -.
DR   Proteomes; UP000002494; Chromosome 3.
DR   Bgee; ENSRNOG00000015396; Expressed in frontal cortex and 19 other cell types or tissues.
DR   ExpressionAtlas; P16086; baseline and differential.
DR   GO; GO:0030054; C:cell junction; IBA:GO_Central.
DR   GO; GO:0042995; C:cell projection; IBA:GO_Central.
DR   GO; GO:0030864; C:cortical actin cytoskeleton; IBA:GO_Central.
DR   GO; GO:0030863; C:cortical cytoskeleton; ISO:RGD.
DR   GO; GO:0032437; C:cuticular plate; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005916; C:fascia adherens; ISO:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0016328; C:lateral plasma membrane; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0033010; C:paranodal junction; ISO:RGD.
DR   GO; GO:0033270; C:paranode region of axon; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:RGD.
DR   GO; GO:0098794; C:postsynapse; IDA:SynGO.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0008091; C:spectrin; TAS:RGD.
DR   GO; GO:0030018; C:Z disc; ISO:RGD.
DR   GO; GO:0051015; F:actin filament binding; IBA:GO_Central.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:RGD.
DR   GO; GO:0030507; F:spectrin binding; IDA:MGI.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0051693; P:actin filament capping; IEA:UniProtKB-KW.
DR   CDD; cd00051; EFh; 1.
DR   CDD; cd11808; SH3_Alpha_Spectrin; 1.
DR   CDD; cd00176; SPEC; 12.
DR   Gene3D; 1.20.5.170; -; 1.
DR   Gene3D; 1.20.58.60; -; 20.
DR   Gene3D; 1.10.238.10; EF-hand; 2.
DR   Gene3D; 2.30.30.40; SH3 Domains; 1.
DR   InterPro; IPR035825; Alpha_Spectrin_SH3.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR014837; EF-hand_Ca_insen.
DR   InterPro; IPR018247; EF_Hand_1_Ca_BS.
DR   InterPro; IPR002048; EF_hand_dom.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   InterPro; IPR002017; Spectrin_repeat.
DR   PANTHER; PTHR11915:SF422; PH_9 DOMAIN-CONTAINING PROTEIN-RELATED; 1.
DR   PANTHER; PTHR11915; SPECTRIN/FILAMIN RELATED CYTOSKELETAL PROTEIN; 1.
DR   Pfam; PF13499; EF-hand_7; 1.
DR   Pfam; PF08726; EFhand_Ca_insen; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   Pfam; PF00435; Spectrin; 20.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR01887; SPECTRNALPHA.
DR   SMART; SM00054; EFh; 2.
DR   SMART; SM01184; efhand_Ca_insen; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00150; SPEC; 20.
DR   SUPFAM; SSF47473; EF-hand; 1.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   SUPFAM; SSF46966; Spectrin repeat; 14.
DR   PROSITE; PS00018; EF_HAND_1; 2.
DR   PROSITE; PS50222; EF_HAND_2; 3.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Actin capping; Actin-binding; Calcium;
KW   Calmodulin-binding; Cytoplasm; Cytoskeleton; Direct protein sequencing;
KW   Metal-binding; Phosphoprotein; Reference proteome; Repeat; SH3 domain.
FT   CHAIN           1..2472
FT                   /note="Spectrin alpha chain, non-erythrocytic 1"
FT                   /id="PRO_0000073457"
FT   REPEAT          45..146
FT                   /note="Spectrin 1"
FT                   /evidence="ECO:0000255"
FT   REPEAT          150..251
FT                   /note="Spectrin 2"
FT                   /evidence="ECO:0000255"
FT   REPEAT          256..358
FT                   /note="Spectrin 3"
FT                   /evidence="ECO:0000255"
FT   REPEAT          361..465
FT                   /note="Spectrin 4"
FT                   /evidence="ECO:0000255"
FT   REPEAT          468..570
FT                   /note="Spectrin 5"
FT                   /evidence="ECO:0000255"
FT   REPEAT          574..676
FT                   /note="Spectrin 6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          679..781
FT                   /note="Spectrin 7"
FT                   /evidence="ECO:0000255"
FT   REPEAT          785..888
FT                   /note="Spectrin 8"
FT                   /evidence="ECO:0000255"
FT   REPEAT          891..961
FT                   /note="Spectrin 9"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          967..1026
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   REPEAT          1096..1166
FT                   /note="Spectrin 10"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1233..1336
FT                   /note="Spectrin 11"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1339..1441
FT                   /note="Spectrin 12"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1446..1549
FT                   /note="Spectrin 13"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1552..1656
FT                   /note="Spectrin 14"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1659..1762
FT                   /note="Spectrin 15"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1764..1868
FT                   /note="Spectrin 16"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1871..1974
FT                   /note="Spectrin 17"
FT                   /evidence="ECO:0000255"
FT   REPEAT          1978..2081
FT                   /note="Spectrin 18"
FT                   /evidence="ECO:0000255"
FT   REPEAT          2092..2194
FT                   /note="Spectrin 19"
FT                   /evidence="ECO:0000255"
FT   REPEAT          2206..2310
FT                   /note="Spectrin 20"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          2323..2358
FT                   /note="EF-hand 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          2366..2401
FT                   /note="EF-hand 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   DOMAIN          2404..2439
FT                   /note="EF-hand 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2336
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2338
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2340
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2342
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2347
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2379
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2381
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2383
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2385
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   BINDING         2390
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00448"
FT   SITE            1176..1177
FT                   /note="Cleavage; by mu-calpain"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         587
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P16546"
FT   MOD_RES         637
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         803
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P16546"
FT   MOD_RES         924
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         982
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         999
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1029
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P16546"
FT   MOD_RES         1031
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1041
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1176
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:11971983"
FT   MOD_RES         1190
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P16546"
FT   MOD_RES         1207
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1217
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16641100,
FT                   ECO:0007744|PubMed:22673903"
FT   MOD_RES         1291
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P16546"
FT   MOD_RES         1306
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         1323
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1519
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1550
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1557
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1578
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1615
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         1647
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         2020
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         2052
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MOD_RES         2066
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P16546"
FT   MOD_RES         2421
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13813"
FT   MUTAGEN         985
FT                   /note="E->A: Abolishes interaction with ACP1."
FT                   /evidence="ECO:0000269|PubMed:11971983"
FT   MUTAGEN         1002
FT                   /note="K->E: No effect on interaction with ACP1."
FT                   /evidence="ECO:0000269|PubMed:11971983"
FT   MUTAGEN         1017
FT                   /note="P->L: Abolishes interaction with ACP1."
FT                   /evidence="ECO:0000269|PubMed:11971983"
FT   MUTAGEN         1176
FT                   /note="Y->E: Abolishes in vitro phosphorylation by Src and
FT                   Lck."
FT                   /evidence="ECO:0000269|PubMed:11971983"
FT   CONFLICT        1329
FT                   /note="D -> Y (in Ref. 3; AAA40770)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1514
FT                   /note="V -> L (in Ref. 1; CAA62350)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1702
FT                   /note="L -> A (in Ref. 3; AAA40770)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1971..1972
FT                   /note="KL -> NV (in Ref. 1; CAA62350)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2205..2206
FT                   /note="KL -> NV (in Ref. 1; CAA62350)"
FT                   /evidence="ECO:0000305"
FT   STRAND          971..974
FT                   /evidence="ECO:0007829|PDB:3THK"
FT   STRAND          993..998
FT                   /evidence="ECO:0007829|PDB:3THK"
FT   STRAND          1001..1009
FT                   /evidence="ECO:0007829|PDB:3THK"
FT   STRAND          1012..1017
FT                   /evidence="ECO:0007829|PDB:3THK"
FT   HELIX           1018..1020
FT                   /evidence="ECO:0007829|PDB:3THK"
FT   STRAND          1021..1023
FT                   /evidence="ECO:0007829|PDB:3THK"
SQ   SEQUENCE   2472 AA;  284637 MW;  08DDF01A2871278A CRC64;
     MDPSGVKVLE TAEDIQERRQ QVLDRYHRFK ELSTLRRQKL EDSYRFQFFQ RDAEELEKWI
     QEKLQVASDE NYKDPTNLQG KLQKHQAFEA EVQANSGAIV KLDETGNLMI SEGHFASETI
     RTRLMELHRQ WELLLEKMRE KGIKLLQAQK LVQYLRECED VMDWINDKEA IVTSEELGQD
     LEHVEVLQKK FEEFQTDLAA HEERVNEVNQ FAAKLIQEQH PEEELIKTKQ EEVNAAWQRL
     KGLALQRQGK LFGAAEVQRF NRDVDETIGW IKEKEQLMAS DDFGRDLASV QALLRKHEGL
     ERDLAALEDK VKALCAEADR LQQSHPLSAN QIQVKREELI TNWEQIRTLA AERHARLDDS
     YRLQRFLADF RDLTSWVTEM KALINADELA NDVAGAEALL DRHQEHKGEI DAHEDSFKSA
     DESGQALLAA GHYASDEVRE KLSILSEERA ALLELWELRR QQYEQCMDLQ LFYRDTEQVD
     NWMSKQEAFL LNEDLGDSLD SVEALLKKHE DFEKSLSAQE EKITALDEFA TKLIQNNHYA
     MEDVATRRDA LLSRRNALHE RAMHRRAQLA DSFHLQQFFR DSDELKSWVN EKMKTATDEA
     YKDPSNLQGK VQKHQAFEAE LSANQSRIDA LEKAGQKLID VNHYAKEEVA ARMNEVISLW
     KKLLEATELK GVKLREANQQ QQFNRNVEDI ELWLYEVEGH LASDDYGKDL TNVQNLQKKH
     ALLEADVAAH QDRIDGITIQ ARQFQDAGHF DAENIKKKQE ALVARYEALK EPMVARKQKL
     ADSLRLQQLF RDVEDEETWI REKEPIAAST NRGKDLIGVQ NLLKKHQALQ AEIAGHEPRI
     KAVTQKGNAM VEEGHFAAED VKAKLSELNQ KWEALKAKAS QRRQDLEDSL QAQQYFADAN
     EAESWMREKE PIVGSTDYGK DEDSAEALLK KHEALMSDLS AYGSSIQALR EQAQSCRQQV
     APMDDETGKE LVLALYDYQE KSPREVTMKK GDILTLLNST NKDWWKVEVN DRQGFVPAAY
     VKKLDPAQSA SRENLLEEQG SIALRQGQID NQTRITKEAG SVSLRMKQVE ELYQSLLELG
     EKRKGMLEKS CKKFMLFREA NELQQWINEK EAALTSEEVG ADLEQVEVLQ KKFDDFQKDL
     KANESRLKDI NKVAEDLESE GLMAEEVQAV QQQEVYGMMP RDEADSKTAS PWKSARLMVH
     TVATFNSIKE LNERWRSLQQ LAEERSQLLG SAHEVQRFHR DADETKEWIE EKNQALNTDN
     YGHDLASVQA LQRKHEGFER DLAALGDKVN SLGETAQRLI QSHPESAEDL KEKCTELNQA
     WTSLGKRADQ RKAKLGDSHD LQRFLSDFRD LMSWINGIRG LVSSDELAKD VTGAEALLER
     HQEHRTEIDA RAGTFQAFEQ FGQQLLAHGH YASPEIKEKL DILDQERTDL EKAWVQRRMM
     LDHCLELQLF HRDCEQAENW MAAREAFLNT EDKGDSLDSV EALIKKHEDF DKAINVQEEK
     IAALQAFADQ LIAVDHYAKG DIANRRNEVL DRWRRLKAQM IEKRSKLGES QTLQQFSRDV
     DEIEAWISEK LQTASDESYK DPTNIQSKHQ KHQAFEAELH ANADRIRGVI DMGNSLIERG
     ACAGSEDAVK ARLAALADQW QFLVQKSAEK SQKLKEANKQ QNFNTGIKDF DFWLSEVEAL
     LASEDYGKDL ASVNNLLKKH QLLEADISAH EDRLKDLNSQ ADSLMTSSAF DTSQVKEKRD
     TINGRFQKIK SMATSRRAKL SESHRLHQFF RDMDDEESWI KEKKLLVSSE DYGRDLTGVQ
     NLRKKHKRLE AELAAHEPAI QGVLDTGKKL SDDNTIGQEE IQQRLAQFVE HWKELKQLAA
     ARGQRLEESL EYQQFVANVE EEEAWINEKM TLVASEDYGD TLAAIQGLLK KHEAFETDFT
     VHKDRVNDVC TNGQDLIKKN NHHEENISSK MKGLNGKVSD LEKAAAQRKA KLDENSAFLQ
     FNWKADVVES WIGEKENSLK TDDYGRDLSS VQTLLTKQET FDAGLQAFQQ EGIANITALK
     DQLLAAKHIQ SKAIEARHAS LMKRWTQLLA NSATRKKKLL EAQSHFRKVE DLFLTFAKKA
     SAFNSWFENA EEDLTDPVRC NSLEEIKALR EAHDAFRSSL SSAQADFNQL AELDRQIKSF
     RVASNPYTWF TMEALEETWR NLQKIIKERE LELQKEQRRQ EENDKLRQEF AQHANAFHQW
     IQETRTYLLD GSCMVEESGT LESQLEATKR KHQEIRAMRS QLKKIEDLGA AMEEALILDN
     KYTEHSTVGL AQQWDQLDQL GMRMQHNLEQ QIQARNTTGV TEEALKEFSM MFKHFDKDKS
     GRLNHQEFKS CLRSLGYDLP MVEEGEPDPE FEAILDTVDP NRDGHVSLQE YMAFMISRET
     ENVKSSEEIE SAFRALSSEG KPYVTKEELY QNLTREQADY CVSHMKPYVD GKGRELPTAF
     DYVEFTRSLF VN
//
